Kazia Therapeutics to Engage in In-Depth Conversations at Guggenheim's Healthcare Innovation Conference

Kazia Therapeutics to Participate in Guggenheim's Healthcare Innovation Conference

Kazia Therapeutics Limited, a leader in oncology-focused biotechnology, has announced its participation in the Guggenheim 3rd Annual Healthcare Innovation Conference. The event is scheduled for November 9 to 11, 2026, and will be held in Boston, Massachusetts. This conference presents a unique opportunity for industry leaders to discuss advancements in cancer treatment and innovation.

During this engaging forum, Kazia's Chief Executive Officer, John Friend, MD, and Jeffrey Kraws, the Head of Corporate Strategy and Development, will be featured in a fireside chat designed to provide insights into their ongoing research and development efforts. They will highlight Kazia’s commitment to creating therapies that specifically target the reprogramming of cancer biology, aiming to enhance anti-tumor immunity and provide solutions for resistance to treatments.

The session is set to begin at 8:30 a.m. Eastern Standard Time (EST), and a live webcast will be available for those unable to attend in person. Attendees and stakeholders are encouraged to reach out to their Guggenheim representatives to arrange one-on-one meetings with Kazia's management team during the conference.

Highlights of Kazia Therapeutics

Kazia Therapeutics is notably recognized for its lead asset, Paxalisib, an investigational oral therapy that shows promise as a dual PI3K/mTOR inhibitor. This compound is currently under development to address various forms of cancer, including central nervous system cancers, advanced breast cancer, and colorectal cancer. Importantly, Paxalisib has attained both Fast Track and Orphan Drug designations from the U.S. FDA, particularly for its application in glioblastoma. It has also been designated as a Fast Track therapy for PI3K-altered brain metastases with concurrent radiation treatments, and received acknowledgments for select pediatric brain tumors, including diffuse intrinsic pontine glioma.

In addition to Paxalisib, Kazia is actively pursuing other innovative therapeutic programs. These include NDL2, a groundbreaking nuclear PD-L1 protein degrader targeting a newly identified mechanism of immunotherapy resistance and metastatic spread, and MSETC, a SETDB1 inhibitor intended to restore immune signaling in tumors that have become resistant to existing immunotherapy treatments, such as checkpoint inhibitors. The company is also exploring EVT801, a small molecule VEGFR-3 inhibitor, for possible partnerships moving forward.

The Guggenheim 3rd Annual Healthcare Innovation Conference serves as a significant platform where Kazia hopes to share its scientific advancements and collaborative potentials while also gleaning insights from discussions with peers and other experts in the oncology arena. Kazia Therapeutics is steadfast in its mission to pioneer groundbreaking solutions for patients battling cancer. For those interested in learning more about the company and its initiatives, additional information is available at www.kaziatx.com. For ongoing updates, you can follow Kazia on X and LinkedIn.

In conclusion, the upcoming conference will not only deepen the conversation around cancer research but also foster new relationships in the healthcare ecosystem aimed at improving patient outcomes globally. Kazia's presence at this annual event signifies its dedication to transformative cancer therapies and its leadership role in the biopharmaceutical sector.